All Myriad Oncology Tests
Myriad Oncology offers a suite of tests for 8 different cancer types that can provide answers about how aggressive your cancer may be, if you qualify for or will benefit from certain advanced treatments, and more.
What Tests Does Myriad Oncology Offer?
The Myriad myRisk® Hereditary Cancer Test is a multi-gene panel that determines hereditary cancer risk associated with 8 cancer sites: breast, ovarian, colorectal, endometrial, melanoma, pancreatic, gastric, and prostate. Learn more here.
BRACAnalysis CDx® is an FDA-approved blood test used to identify patients with germline BRCA1/2 mutations who are eligible for certain targeted therapies. This test quickly and accurately provides results for patients with metastatic pancreatic cancer, metastatic breast cancer, ovarian cancer, and metastatic prostate cancer.
myChoice® CDx is the most comprehensive tumor test that determines HRD status in patients with ovarian cancer. This FDA-approved test helps provide information on the benefit of targeted therapy for your ovarian cancer.
EndoPredict® is a tumor test designed for women with ER+/HER2-, early-stage, node-negative or node-positive breast cancer. EndoPredict tailors treatment decisions based on results that are specific to your cancer.
Prolaris® is a tumor aggressiveness test for patients with prostate cancer that can help determine how quickly prostate cancer will progress.
myPath® Melanoma is a test that analyzes suspicious skin lesions at the molecular level to help determine its diagnosis, a correct diagnosis will ensure you have the best treatment path going forward.
